Median OS was similar in the sorafenib plus erlotinib and sorafenib plus placebo groups ( 9.5 v 8.5 months , respectively ; hazard ratio [ HR ] , 0.929 ; P = .408 ) , as was median time to progression ( 3.2 v 4.0 months , respectively ; HR , 1.135 ; P = .18 ) .